Introduction
In 2005, over 50.000 solid organ transplants were conducted in the seven major markets. In order to prevent the patient's immune system from rejecting the transplanted organ, immunosuppression therapy is required for the lifetime of the graft with a base maintenance drug (either Calcineurin- or mTOR inhibitors) and adjunctive therapies (antimetabolites, steroids).

Scope
The report focuses on current and future therapies used for immunosuppression in solid organ transplantation, with sales and volume forecasts to 2015
Assessment of current and future dynamics, opportunities and threats for immunosuppressants across the seven major markets
Overview of organ supply, national donation rates, waiting lists and forecasts of the number of transplants and maintenance population to 2015
Assessment of key factors affecting prescription choice, including analysis of regional differences
Highlights
The transplantation market poses unusual challenges to pharmaceutical companies, the most significant one being a lack of donor organs: the waiting list for transplants will continue to grow faster than the number of available organs. Another challenge is the static nature of the market: maintenance regimens of stable patients rarely get changed.

The market for immusuppresssants used in transplantation is set to grow to $4.3 billion by 2015s. Despite changing protocols, the leading drug class by value should continue to be calcineurin inhibitors with a 37% market share, followed by mTOR inhibitors.

mTOR inhibitors are expected to be the fastest growing class, driven by Wyeth's Rapamune. Datamonitor foresees the drug to gain a greater role as a primary immunsuppressant despite current tolerability issues. Bristol Myers Squibb's injectable fusion protein belatacept may offer another alternative to calcineurin inhibitors

Reasons to Purchase
Identify and understand the dynamics in immunosuppressive protocols as reflected in opinion leaders' thoughts
Quantify the future immunosuppressant market size by volume and value for each of the seven major markets
Quantify the future market size based on transplant types, numbers and the maintenance population